WB-DW-MRI vs CHOLINE-PET/CT for Selecting Treatments in Recurrent Prostate Cancer
WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING (WB-DW-MRI) VS CHOLINE-POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY (CHOLINE- PET/CT) for Selecting Treatments in Recurrent Prostate Cancer
1 other identifier
observational
46
0 countries
N/A
Brief Summary
The purpose of this study is to determine the effectiveness of whole-body diffusion-weighted magnetic resonance imaging (WB-DW- MRI) in detecting metastases by comparing the results with those from choline-positron emission tomography-computed tomography (choline-PET/CT) in patients with metastatic/oligometastatic prostate cancer. Patients with this disease profile who could benefit from treatment with stereotactic body radiation therapy (SBRT) were selected and their responses to these techniques were rated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2014
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2015
CompletedFirst Submitted
Initial submission to the registry
August 3, 2016
CompletedFirst Posted
Study publicly available on registry
August 8, 2016
CompletedAugust 9, 2016
August 1, 2016
5 months
August 3, 2016
August 6, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
effectiveness of whole-body diffusion-weighted magnetic resonance imaging (WB-DW- MRI) in detecting metastases
2 years
Interventions
Choline-PET/CT versus NMRscan comparative study
Eligibility Criteria
46 consecutive patients given a diagnosis of prostate cancer by the Radiation Oncology Department of our center, between October 2014 and March 2015 who met the established inclusion criteria: a histological diagnosis of prostate cancer, and after treatment of the primary disease, a diagnosis of biochemical relapse and no metastases or oligometastatic stage (less than 5 lesions) in conventional diagnostic images (bone scintigraphy, chest-abdominal and pelvic CT and pelvic MRI).
You may qualify if:
- Prostate cancer histologic diagnostic after one treatment
- o less lessions
- Asimptomatic lessions
- Informed Consent Form signed
You may not qualify if:
- Not capability to perform NMR os CT/PET scans
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Conde-Moreno AJ, Herrando-Parreno G, Muelas-Soria R, Ferrer-Rebolleda J, Broseta-Torres R, Cozar-Santiago MP, Garcia-Pinon F, Ferrer-Albiach C. Whole-body diffusion-weighted magnetic resonance imaging (WB-DW-MRI) vs choline-positron emission tomography-computed tomography (choline-PET/CT) for selecting treatments in recurrent prostate cancer. Clin Transl Oncol. 2017 May;19(5):553-561. doi: 10.1007/s12094-016-1563-4. Epub 2016 Oct 31.
PMID: 27796820DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Antonio J Conde Moreno, MD PhD
Hospital Provincial de Castellon
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD PhD
Study Record Dates
First Submitted
August 3, 2016
First Posted
August 8, 2016
Study Start
October 1, 2014
Primary Completion
March 1, 2015
Study Completion
March 1, 2015
Last Updated
August 9, 2016
Record last verified: 2016-08
Data Sharing
- IPD Sharing
- Will not share